
EquitySector - HealthcareVery High Risk
Regular
NAV (15-Apr-26)
Returns (Since Inception)
Fund Size
₹556 Cr
Expense Ratio
2.37%
ISIN
INF03VN01878
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
06 Feb 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+10.13%
+7.09% (Cat Avg.)
Since Inception
+15.90%
— (Cat Avg.)
| Equity | ₹545.55 Cr | 98.05% |
| Others | ₹10.87 Cr | 1.95% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹68.7 Cr | 12.35% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹49.54 Cr | 8.90% |
| Lupin Ltd | Equity | ₹32.1 Cr | 5.77% |
| Divi's Laboratories Ltd | Equity | ₹29.57 Cr | 5.31% |
| Cash Offset For Derivatives | Cash - General Offset | ₹-25.47 Cr | 4.58% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹23.58 Cr | 4.24% |
| Laurus Labs Ltd | Equity | ₹21.85 Cr | 3.93% |
| Fortis Healthcare Ltd | Equity | ₹21.41 Cr | 3.85% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹21.09 Cr | 3.79% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹17.65 Cr | 3.17% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹17.57 Cr | 3.16% |
| Aurobindo Pharma Ltd | Equity | ₹16.78 Cr | 3.02% |
| Sai Life Sciences Ltd | Equity | ₹15.41 Cr | 2.77% |
| Net Receivables / (Payables) | Cash - Collateral | ₹15.31 Cr | 2.75% |
| Acutaas Chemicals Ltd | Equity | ₹14.54 Cr | 2.61% |
| Corona Remedies Ltd | Equity | ₹12.61 Cr | 2.27% |
| Ipca Laboratories Ltd | Equity | ₹12.08 Cr | 2.17% |
| Ajanta Pharma Ltd | Equity | ₹11.73 Cr | 2.11% |
| Aurobindo Pharma Limited | Equity - Future | ₹11.28 Cr | 2.03% |
| Emcure Pharmaceuticals Ltd | Equity | ₹10.49 Cr | 1.89% |
| Narayana Hrudayalaya Ltd | Equity | ₹9.55 Cr | 1.72% |
| Shaily Engineering Plastics Ltd | Equity | ₹8.81 Cr | 1.58% |
| Thyrocare Technologies Ltd | Equity | ₹8.67 Cr | 1.56% |
| Neuland Laboratories Ltd | Equity | ₹7.87 Cr | 1.42% |
| Navin Fluorine International Ltd | Equity | ₹7.86 Cr | 1.41% |
| Aether Industries Ltd | Equity | ₹7.68 Cr | 1.38% |
| Pfizer Ltd | Equity | ₹7.52 Cr | 1.35% |
| Dr. Lal PathLabs Ltd | Equity | ₹7.44 Cr | 1.34% |
| Strides Pharma Science Ltd | Equity | ₹6.9 Cr | 1.24% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹6.68 Cr | 1.20% |
| AstraZeneca Pharma India Ltd | Equity | ₹5.93 Cr | 1.07% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹5.23 Cr | 0.94% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹5.15 Cr | 0.93% |
| Dr. Reddy's Laboratories Limited | Equity - Future | ₹4.96 Cr | 0.89% |
| Tbill | Bond - Gov't/Treasury | ₹4.96 Cr | 0.89% |
| 28/05/2026 Maturing 182 DTB | Bond - Gov't/Treasury | ₹4.96 Cr | 0.89% |
| Zydus Lifesciences Ltd | Equity | ₹4.6 Cr | 0.83% |
| Rainbow Childrens Medicare Ltd | Equity | ₹4.47 Cr | 0.80% |
| Divi's Laboratories Limited | Equity - Future | ₹4.35 Cr | 0.78% |
| Dr Reddy's Laboratories Ltd | Equity | ₹4.14 Cr | 0.74% |
| Poly Medicure Ltd | Equity | ₹3.9 Cr | 0.70% |
| Sudeep Pharma Ltd | Equity | ₹3.73 Cr | 0.67% |
| Supriya Lifescience Ltd | Equity | ₹3.56 Cr | 0.64% |
| Zota Health Care Ltd | Equity | ₹3.07 Cr | 0.55% |
| Aarti Pharmalabs Ltd | Equity | ₹2.66 Cr | 0.48% |
| Max Healthcare Institute Limited | Equity - Future | ₹2.18 Cr | 0.39% |
| Tbill | Bond - Gov't/Treasury | ₹1.98 Cr | 0.36% |
| Apollo Hospitals Enterprise Limited | Equity - Future | ₹1.77 Cr | 0.32% |
| Tatva Chintan Pharma Chem Ltd | Equity | ₹1.18 Cr | 0.21% |
| Orchid Pharma Ltd | Equity | ₹1.08 Cr | 0.19% |
| Tbill | Bond - Gov't/Treasury | ₹0.99 Cr | 0.18% |
| Tbill | Bond - Gov't/Treasury | ₹0.99 Cr | 0.18% |
| India (Republic of) | Bond - Short-term Government Bills | ₹0.99 Cr | 0.18% |
| Alkem Laboratories Ltd | Equity | ₹0.85 Cr | 0.15% |
| Tbill | Bond - Gov't/Treasury | ₹0.79 Cr | 0.14% |
| Sun Pharmaceutical Industries Limited | Equity - Future | ₹0.56 Cr | 0.10% |
| Fortis Healthcare Limited | Equity - Future | ₹0.37 Cr | 0.07% |
| 09/04/2026 Maturing 182 DTB | Bond - Gov't/Treasury | ₹0.2 Cr | 0.04% |
Large Cap Stocks
26.43%
Mid Cap Stocks
24.60%
Small Cap Stocks
42.44%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹480.01 Cr | 86.27% |
| Basic Materials | ₹40.07 Cr | 7.20% |
Standard Deviation
This fund
--
Cat. avg.
16.46%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.96
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.70
Higher the better

Since February 2024

Since February 2024
Since May 2025
Since February 2024
Since January 2025
ISIN INF03VN01878 | Expense Ratio 2.37% | Exit Load 1.00% | Fund Size ₹556 Cr | Age 2 years 2 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹33,884 Cr
Address
1&2 Senapati Bapat Marg, Elphinstone Road (West) Mumbai Mumbai City, Mumbai
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments